Valneva SE (VALN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerning factors: declining gross margins, increased losses, and higher financial expenses. The Q&A section highlights uncertainties regarding the Lyme disease vaccine's clinical evidence and FDA interactions. Additionally, the decline in IXIARO growth and potential revenue risks due to geopolitical factors contribute to a negative outlook. While there are efforts to address concerns and expand the R&D pipeline, the lack of clear guidance and immediate positive catalysts suggest a negative stock price movement in the short term.
Key Financial Performance
Product Sales EUR 30.5 million compared to EUR 48.6 million 1 year ago. The year-over-year decline is primarily a result of a difference in the phasing of scheduled deliveries to the U.S. Department of Defense.
IXIARO Sales EUR 20.2 million compared to EUR 27.5 million in the first quarter of 2025. The decline was driven by the phasing of scheduled deliveries to the U.S. Department of Defense.
DUKORAL Sales EUR 8.6 million compared to EUR 12.3 million in the first quarter of last year. The prior year included one-off sales related to the supply of doses to Mayotte following a local cholera outbreak. Additionally, sales were impacted by a change in the distribution partner for certain EU countries.
IXCHIQ Sales EUR 1.6 million compared to EUR 3 million in the first quarter of 2025. The decline was due to the absence of first shipment doses to French islander la Reynie and lower travel sales in the United States.
Third-party Products EUR 100,000 compared to EUR 5.8 million in last year's first quarter. The decline reflects the intentional wind down of third-party product distribution to focus on proprietary products.
Total Revenues EUR 30.9 million versus EUR 49.2 million in the first 3 months of 2025. The decline was due to lower product sales.
Cost of Goods and Services EUR 26.2 million versus EUR 21.3 million in the prior year. The increase was due to idle costs, failed batches, inventory provisions, and onerous contracts related to IXCHIQ.
Gross Margin on Commercial Product Sales (excluding IXCHIQ) 45.2% compared to 62.7% for the 3 months ended March 31, 2025. The decline was driven by higher manufacturing costs, increased batch write-offs, and lower overhead absorption.
IXIARO Gross Margin 50.8% compared to 72.6% in the first quarter of 2025. The decline was driven by higher manufacturing costs, increased batch write-offs, and lower overhead absorption.
Operating Loss Minus EUR 23.7 million, driven by lower sales and gross margin.
Net Finance and Income Tax Expense EUR 8.4 million compared to EUR 3.3 million in the prior year. The increase was driven by a foreign exchange loss of EUR 3 million compared to a foreign exchange gain of EUR 3.7 million in the prior year.
Loss for the First Quarter EUR 32.1 million compared to EUR 9.2 million in the prior year. The increase was driven by lower sales, gross margin, and higher finance expenses.
Cash and Cash Equivalents EUR 105 million at the end of March compared to EUR 110 million at the end of the prior fiscal year. The decrease reflects reduced cash used in operations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Lyme Disease Vaccine (VLA15): Phase III trial showed strong efficacy above 70%, with one statistical criterion met. Pfizer plans regulatory submissions. The vaccine addresses a major unmet medical need with a growing disease burden in high-risk areas.
Chikungunya Vaccine (IXCHIQ): Pilot vaccination campaign in Brazil aims for 20%-40% coverage in adults aged 18-59. Over 30,000 vaccinated so far, targeting 100,000. Locally produced vaccine achieved licensure in Brazil.
Shigella Vaccine: Advanced tetravalent vaccine candidate targeting four common pathogenic Shigella bacteria. Two ongoing studies with results expected in summer 2026. Potential market exceeds $0.5 billion annually.
Lyme Disease Vaccine Market: Addresses a highly underserved market with no current vaccine. High-risk population includes 90 million in North America and 200 million in Europe.
Chikungunya Vaccine Market: Focus on emerging markets and low-medium income countries. Expansion of manufacturing and distribution networks ongoing.
Cost Reduction: Global workforce reduction of 10%-15% planned, aiming for a 25%-35% reduction in operating expenses compared to 2025.
Revenue Guidance: Adjusted product sales guidance to EUR 135-150 million for 2026 due to adverse trends in travel vaccine uptake.
Strategic Growth: Focus on scaling R&D pipeline post-approval of Lyme vaccine. Plans to expand beyond vector-borne diseases into areas like enteric diseases and EBV.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Lyme Vaccine Development: Uncertainty around the Lyme vaccine candidate due to statistical criteria not being fully met, leading to potential regulatory and market risks.
Financial Performance: Decline in product sales and gross margins compared to the previous year, driven by higher manufacturing costs, batch write-offs, and lower overhead absorption.
Travel Vaccine Uptake: Emerging adverse trends in travel vaccine uptake across key markets, influenced by geopolitical factors, impacting revenue projections.
Operational Restructuring: Planned global workforce reduction of 10%-15% and operating expense cuts of 25%-35%, which may impact employee morale and operational efficiency.
Manufacturing Costs: Higher manufacturing costs following the transfer of production to a new facility, leading to increased costs and reduced gross margins.
Chikungunya Vaccine Sales: Lower-than-anticipated sales of the Chikungunya vaccine, resulting in cancellation fees and negative gross margins.
Foreign Exchange Losses: Significant foreign exchange losses impacting financial performance.
Supply Chain Adjustments: Adverse impacts from changes in distribution partners and inventory transfers, particularly affecting DUKORAL sales.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Lyme Vaccine Candidate (VLA15): Pfizer plans to submit the Lyme vaccine candidate to regulatory authorities. If successful, this vaccine could address a major unmet medical need, with a growing disease burden in high-risk areas. Valneva plans to leverage its vaccine development expertise for strategic growth opportunities post-approval.
Chikungunya Vaccine (IXCHIQ): A pilot vaccination campaign is ongoing in Brazil, targeting 20%-40% coverage in adults aged 18-59. Over 30,000 individuals have been vaccinated, with a goal of exceeding 100,000. Efforts are underway to expand manufacturing and distribution networks in endemic countries.
Shigella Vaccine Program: Two studies are ongoing, with readouts expected in summer 2026. Future development steps will be decided based on these results. The program targets a global market exceeding €0.5 billion annually.
Financial Guidance for FY 2026: Product sales guidance has been adjusted to €135 million-€150 million, and total revenues to €145 million-€160 million, due to adverse trends in travel vaccine uptake. Operating expenses are expected to decrease by 25%-35% compared to 2025, supported by a global workforce reduction of 10%-15%.
Strategic Focus and R&D Pipeline: Valneva plans to build scale in its R&D pipeline post-approval of the Lyme vaccine, focusing on both organic and inorganic growth. The company aims to expand beyond vector-borne diseases into areas like enteric diseases and EBV.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the status of Pfizer's pre-BLA meeting request with the FDA for the Lyme program?
A:Pfizer is preparing for respective meetings, but no further details or timing can be provided at this point.
Q:How does Pfizer plan to present the totality of clinical evidence to the FDA for the Lyme program?
A:The management could not comment on this question.
Q:Will there be a disclosure around the BLA acceptance once Pfizer has the BLA meeting scheduled?
A:The current hypothesis is that file acceptance will be disclosed.
Q:What caused the decline in IXIARO growth dynamics in Q1, and what is the basis for the full-year 2026 guidance adjustment?
A:The decline was driven by a combination of factors, primarily the phasing of supplies to the U.S. Department of Defense (DoD), which is the largest customer for IXIARO. Reduced travel and shifting of distributors also contributed. The guidance adjustment reflects reduced travel dynamics and airline data trends.
Q:When will the full data for the Lyme program be released, and are there comparable vaccine cases where the primary endpoint was not met but the vaccine was still approved?
A:Pfizer plans to present the full data set at a forthcoming conference, but the specific conference has not been confirmed. There are some comparable cases, such as Fluad and RSV vaccines, but none are directly comparable. The review will focus on the totality of clinical evidence.
Q:What is the impact of the lower-than-expected event rate in the Lyme vaccine trial on commercial opportunities?
A:The total number of reported and adjudicated cases was lower than anticipated, but this does not necessarily reflect what is happening in high-risk areas. Pfizer is investigating this further.
Q:Can you elaborate on the restructuring plan, including savings phasing, split between R&D and SG&A, and payback timing?
A:The redundancy process in Austria will take time due to legal processes and notice periods, with full payback expected next year. Most savings will come from R&D, with minor savings in SG&A and G&A. External spend savings have already been initiated.
Q:What level of insight does the company have into Pfizer's FDA discussions?
A:The company is not actively involved in Pfizer's discussions with the FDA but is informed through existing steering structures at different time points compared to the market.
Q:What is the normalized gross margin for 2026, and what is the impact of idle capacity costs?
A:The normalized gross margin is expected to be close to the full-year 2025 level. Idle capacity costs are slightly higher than last year due to the transition to the Almeida facility, which increased idle capacity costs.
Q:Is there further downside risk to revenue guidance for 2026?
A:The company believes the guidance range of EUR 130 million to EUR 150 million is realistic. However, geopolitical situations, such as the Middle East conflict, could impact the travel market and revenues.
Q:What are the expectations for the Shigella Phase II readout, and how does it align with OpEx reduction?
A:The readout will focus on pilot efficacy, immunogenicity, and schedule optimization. There is no strategic change due to OpEx reduction, but the pace may differ. Commercialization strategies include targeting emerging markets and travelers, with potential combination vaccines for travelers' diarrhea.
Q:What measures are being taken to address the FDA's concerns about the Almeida facility for IXIARO production?
A:The company is addressing the FDA's concerns and will resubmit the pre-approval supplement process. The existing facility is still active and supplying IXIARO to the U.S. market, so no impact on sales is expected.
Q:Review of Unclear Management Responses
A:Management avoided giving direct answers to questions about Pfizer's plans to present clinical evidence to the FDA and the timing of the pre-BLA meeting. Additionally, they did not provide clarity on the impact of the lower event rate in the Lyme vaccine trial on commercial opportunities.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Almeida facility
Butantan
Chikungunya
EUR decline
EUR decrease
EUR sale
RD activity
analysis
change
child
completion
contract
cost good
coverage
criterion
delivery
disease burden
distribution partner
effect
exchange
expense EUR
facility batch
factor
finance
inventory
loss EUR
manufacturing transfer
product EUR
project
risk area
sale EUR
shigellosis
slide
solution
submission authority
travel
workforce reduction
VALN Transcript
Valneva SE (VALN) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals several concerning factors: declining gross margins, increased losses, and higher financial expenses. The Q&A section highlights uncertainties regarding the Lyme disease vaccine's clinical evidence and FDA interactions. Additionally, the decline in IXIARO growth and potential revenue risks due to geopolitical factors contribute to a negative outlook. While there are efforts to address concerns and expand the R&D pipeline, the lack of clear guidance and immediate positive catalysts suggest a negative stock price movement in the short term.
Valneva SE (VALN) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call reflects a concerning financial situation with significant losses and negative EBITDA. Despite promising vaccine developments, uncertainties around timelines and guidance, particularly regarding the Lyme disease vaccine, contribute to a negative outlook. Management's inability to provide clear updates and reliance on Pfizer for key information further exacerbates investor concerns. The financial guidance and strategic plans do not offset the current financial losses, leading to a negative sentiment.
Valneva SE (VALN) Q3 2025 Earnings Call Transcript
Unknown11-20
The earnings call revealed mixed financial performance, with a significant operating loss and negative EBITDA largely due to the absence of last year's PRV sale. While there were improvements in gross margins, the temporary U.S. license suspension for IXCHIQ and unclear FDA timelines add uncertainty. The Q&A highlighted management's lack of specific guidance on key issues like IXCHIQ's suspension and DUKORAL's growth in Germany, leading to a negative sentiment. The absence of clear guidance and the mixed financial results suggest a likely negative stock price reaction.
Valneva SE (VALN) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call reveals mixed signals. While there are strong regulatory achievements and promising vaccine developments, the financial performance shows significant operating losses and reduced cash position. Guidance remains steady, but the lack of additional revenue recognition and vague responses in the Q&A highlight uncertainties. The operational cash burn reduction is positive, but overall, the sentiment is balanced by both positive and negative factors, leading to a neutral outlook.
VALN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
